0 533

Cited 12 times in

Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.

DC Field Value Language
dc.contributor.author홍성준-
dc.date.accessioned2015-12-28T11:02:31Z-
dc.date.available2015-12-28T11:02:31Z-
dc.date.issued2014-
dc.identifier.issn0919-8172-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/138566-
dc.description.abstractOBJECTIVES: To evaluate the safety and efficacy of abiraterone acetate and prednisolone in Korean and Taiwanese patients with metastatic castration-resistant prostate cancer not responding to docetaxel-based chemotherapy. METHODS: In this single-arm study, 82 metastatic castration-resistant prostate cancer patients who failed docetaxel-based chemotherapy were treated with abiraterone (1000 mg, once daily) and prednisolone (5 mg, twice daily). Patients achieving a prostate-specific antigen decline ≥ 50% were considered as responding. RESULTS: A total of 35 patients (43%) achieved prostate-specific antigen response (95% confidence interval 32-54). The median time to prostate-specific antigen progression was 4.7 months (95% confidence interval 3.7-8.3); the median overall survival was 11.8 months. Two (4%) of 50 patients with measurable disease achieved partial response. The median testosterone concentration was in the castration range (1.21 nmol/L) throughout the treatment period. Median dehydroepiandrosterone sulfate decreased from 0.725 μmol/L (baseline) to 0.080 μmol/L (cycle 4). The most common adverse event was bone pain (20%); grade 3/4 adverse event of special interest were hypokalemia (7%), fluid retention and liver function abnormalities (5% each), hypertension (2%), and cardiac disorders (1%). CONCLUSIONS: A combination of abiraterone acetate and prednisolone appears to be a favorable second-line treatment in Taiwanese and Korean patients with advanced metastatic castration-resistant prostate cancer after failed docetaxel-based chemotherapy.-
dc.description.statementOfResponsibilityopen-
dc.format.extent1239~1244-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHAndrogens/metabolism*-
dc.subject.MESHAndrostenes/administration & dosage*-
dc.subject.MESHAntineoplastic Agents/administration & dosage-
dc.subject.MESHDisease Progression-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHGlucocorticoids/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHIncidence-
dc.subject.MESHMale-
dc.subject.MESHOrchiectomy*-
dc.subject.MESHPrednisolone/administration & dosage*-
dc.subject.MESHProstatic Neoplasms, Castration-Resistant/drug therapy*-
dc.subject.MESHProstatic Neoplasms, Castration-Resistant/epidemiology-
dc.subject.MESHProstatic Neoplasms, Castration-Resistant/secondary-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHSurvival Rate/trends-
dc.subject.MESHTaiwan/epidemiology-
dc.subject.MESHTaxoids/therapeutic use*-
dc.subject.MESHTreatment Failure-
dc.titleAbiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨기과학)-
dc.contributor.googleauthorCheol Kwak-
dc.contributor.googleauthorTony Tong Lin Wu-
dc.contributor.googleauthorHyun Moo Lee-
dc.contributor.googleauthorHsi Chin Wu-
dc.contributor.googleauthorSung Joon Hong-
dc.contributor.googleauthorYen Chuan Ou-
dc.contributor.googleauthorSeok Soo Byun-
dc.contributor.googleauthorHyou Young Rhim-
dc.contributor.googleauthorThian Kheoh-
dc.contributor.googleauthorYing Wan-
dc.contributor.googleauthorHoward Yeh-
dc.contributor.googleauthorMargaret K Yu-
dc.contributor.googleauthorChoung Soo Kim-
dc.identifier.doi10.1111/iju.12589-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04402-
dc.relation.journalcodeJ01169-
dc.identifier.eissn1442-2042-
dc.identifier.pmid25099185-
dc.identifier.urlhttp://onlinelibrary.wiley.com/doi/10.1111/iju.12589/abstract-
dc.subject.keywordabiraterone acetate-
dc.subject.keyworddocetaxel-
dc.subject.keywordmetastatic castration-resistant prostate cancer-
dc.subject.keywordprednisolone-
dc.subject.keywordprostate-specific antigen-
dc.contributor.alternativeNameHong, Sung Joon-
dc.contributor.affiliatedAuthorHong, Sung Joon-
dc.rights.accessRightsfree-
dc.citation.volume21-
dc.citation.number12-
dc.citation.startPage1239-
dc.citation.endPage1244-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF UROLOGY, Vol.21(12) : 1239-1244, 2014-
dc.identifier.rimsid38407-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.